Outlook Therapeutics director buys 34K shares
Outlook Therapeutics, Inc. director Yezan Munther Haddadin reported an open-market purchase of the company’s Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Outlook Therapeutics, Inc. director Yezan Munther Haddadin reported an open-market purchase of the company’s Common Stock. On May 26, 2026, he bought 34,000 shares at $0.44 per share. Following this transaction, he directly owns 37,167 shares of Outlook Therapeutics common stock.
Insider Trade Summary
Net Buyer: 34,000 shares
Net Buy
1 txn
Insider
Haddadin Yezan Munther
Role
Director
Bought
34,000 shs ($15K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 34,000 | $0.44 | $15K |
Holdings After Transaction:
Common Stock — 37,167 shares (Direct)
Key Figures
Shares purchased: 34,000 shares
Purchase price: $0.44 per share
Shares owned after transaction: 37,167 shares
3 metrics
Shares purchased
34,000 shares
Open-market purchase of Common Stock on May 26, 2026
Purchase price
$0.44 per share
Price paid for Outlook Therapeutics Common Stock
Shares owned after transaction
37,167 shares
Total Common Stock directly owned following the purchase
Key Terms
open-market purchase, Common Stock, Form 4
3 terms
open-market purchase financial
"described as an open-market purchase of Common Stock at $0.44 per share"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Common Stock financial
"the security title is identified as Common Stock in the transaction"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"disclosed in the Form 4 insider trading report for this transaction"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Outlook Therapeutics (OTLK) report on this Form 4?
Outlook Therapeutics reported that director Yezan Munther Haddadin executed an open-market purchase of Common Stock. He bought 34,000 shares at $0.44 per share, as disclosed in the Form 4 insider trading report filed for this transaction.
What are Yezan Munther Haddadin’s holdings in Outlook Therapeutics (OTLK) after the transaction?
After the reported transaction, director Yezan Munther Haddadin directly owns 37,167 shares of Outlook Therapeutics Common Stock. This post-transaction balance is disclosed in the Form 4 under total shares beneficially owned following the reported purchase.
Was the Outlook Therapeutics (OTLK) insider trade a purchase or a sale?
The insider trade was a purchase. The Form 4 shows transaction code “P” and describes it as an open-market purchase, indicating that director Yezan Munther Haddadin bought 34,000 shares of Common Stock at $0.44 per share.
What type of security did the Outlook Therapeutics (OTLK) director acquire?
The director acquired Common Stock of Outlook Therapeutics, Inc. The Form 4 identifies the security title as “Common Stock” and records an open-market purchase of 34,000 shares at a price of $0.44 per share.
Is the Outlook Therapeutics (OTLK) insider ownership direct or indirect after this trade?
The ownership reported after this trade is direct. The Form 4 lists the ownership code as “D” for direct, with 37,167 shares of Outlook Therapeutics Common Stock held directly by director Yezan Munther Haddadin following the purchase.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates